Caring to make a difference
Genscreen announces that the in-house RESET project has completed initial testing and shall be renamed “Hervian”
Ian Dixon, CEO of Genscreen Pty Ltd, announces that Genscreen is presently having TR400 drugs sythesised by a contractor. It is anticipated that screening results will be ready for review by March 2010
Genscreen announces the interim results of its preclinical development projects
Genscreen commences work with Qubist Molecular Design (www.qubistmd.com)
Genscreen Pty Ltd announces that it has reduced its operations to concentrate on core activities
Genscreen announces its move to Suite 52, 12 Collins Street Melbourne…
[Read more →]
Tags: news